Fifth Third Bancorp Summit Therapeutics Inc. Transaction History
Fifth Third Bancorp
- $28.3 Billion
- Q2 2025
A detailed history of Fifth Third Bancorp transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 3,000 shares of SMMT stock, worth $62,699. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,000
Previous 3,000
-0.0%
Holding current value
$62,699
Previous $57,000
10.53%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
260Shares Held
90.4MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$705 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$181 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$165 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$84 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$81.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.21B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...